Activated donor immune cells may prevent severe complication after allogeneic stem cell tr
Audio narration · Coming soon
A clinical trial shows that activated regulatory T cells derived from healthy donors can prevent graft-versus-host disease after allogeneic stem cell transplantation, with promising Phase I/II results.
Why this matters
PRISM scored this story 75/100 for interest.
Originally published by gnews